Accordingly, this study identifies two evolutionarily conserved SL interactions, namely BLM SOD1 and CHEK2 SOD1, and defines SOD1 as a novel candidate drug target in cancers harboring BLM and CHEK2 defects. Here, CHEK2 is linked to cancer.